Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Camurus AB ( (SE:CAMX) ) has provided an announcement.
Camurus announced positive results from its POSITANO Phase 2b study, which evaluated the efficacy and safety of CAM2029 in patients with polycystic liver disease (PLD). The study demonstrated that CAM2029 significantly reduces liver and cyst volume compared to placebo and improves symptoms, addressing a high unmet medical need in PLD treatment. Following these results, Camurus plans to discuss a Phase 3 study with regulatory authorities, potentially enhancing its positioning in the biopharmaceutical industry and offering hope to PLD patients.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is a science-led biopharmaceutical company focused on developing and commercializing innovative, long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal technology, Camurus has a diverse R&D pipeline targeting dependence, pain, cancer, and endocrine diseases. The company operates across Europe, the US, and Australia, with headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 181,489
Current Market Cap: SEK35.5B
Learn more about CAMX stock on TipRanks’ Stock Analysis page.